New Zealand introduced random roadside oral fluid drug testing in December 2025, becoming one of the few countries to apply a strict presence-based standard — meaning drivers commit an offence simply by having a detectable drug in their saliva or blood, regardless of whether they are actually impaired to drive.

The Policy: NZTA Drug Driving Changes — December 2025 →

What it does

The Land Transport (Drug Driving) Amendment Act 2025 (Act No 12 of 2025) created a new random roadside oral fluid (saliva) testing regime. Key features:

• Any driver can be stopped at any time — no suspicion of drug use is required. The Attorney-General found this inconsistent with the New Zealand Bill of Rights Act right against unreasonable search, but Parliament proceeded.
• The offence is presence-based, not impairment-based. A driver commits an infringement if an approved analyst finds a qualifying drug at or above a threshold in their saliva or blood — proof of actual impairment is not required.
• The roadside device (Securetec DrugWipe 3 S) screens for four substances only: THC (cannabis), methamphetamine, MDMA, and cocaine.
• Two consecutive positive roadside tests trigger an immediate 12-hour driving prohibition and a saliva sample sent to the PHF Science laboratory.
• The laboratory tests for all 25 Schedule 5 qualifying drugs, including 21 prescription medicines (benzodiazepines, opioids, zopiclone, ketamine, tramadol, and more).
• Penalties for an infringement (single drug found in lab): $200 fine and 50 demerit points. Two or more drugs: $400 fine and 75 demerit points. Refusal: $400 fine, 75 demerit points, and a 12-hour driving ban.
• Criminal charges arise only when blood test results exceed the higher "high-risk" Schedule 5 thresholds: up to 3 months imprisonment, $4,500 fine, and at least 6 months disqualification for a first or second offence; up to 2 years and $6,000 for third and subsequent offences.
• Rollout began in the Wellington District on 15 December 2025, going nationwide by approximately 1 July 2026. The Road Policing Investment Programme mandates 50,000 tests per fiscal year from 2026–27.

The two-stage test

Stage 1 — Roadside oral fluid screening: A police officer can stop any driver and ask them to wipe the DrugWipe 3 S pads along their tongue. The device returns a result in 7–10 minutes. It detects only THC, methamphetamine, MDMA, and cocaine — it cannot detect any prescription medicine. A negative result means the driver is free to go. A positive result triggers a second roadside screening test. Two consecutive positives impose the 12-hour driving prohibition and a separate saliva sample is collected for laboratory analysis.

Stage 2 — Laboratory evidential analysis: The saliva sample is sent to PHF Science (formerly ESR — the Institute of Environmental Science and Research) for analysis against all 25 Schedule 5 qualifying drugs. This includes 4 illicit substances and 21 prescription medicines. A positive lab result (one drug at or above the oral fluid evidential threshold set by SL 2025/247) triggers an infringement notice. The lab stage is the legally evidential step — a positive roadside screening result alone does not lead to prosecution. Blood testing is not routine; it is required only when a driver cannot provide sufficient saliva, has been in a crash involving death or serious injury with two positive roadside tests, or has failed a Compulsory Impairment Test (CIT). Blood results above the higher Schedule 5 "high-risk" threshold trigger criminal charges rather than infringement notices.

Medicinal cannabis and prescription medicines — the collision

New Zealand has a legal medicinal cannabis scheme (since April 2020) with approximately 60,000 patients holding current prescriptions as of late 2025 — a figure that has grown 14-fold since the scheme launched. Over 380,000 medicinal cannabis product units were supplied in 2025, up from 180,000 in 2023, and at least 20 of the 50+ approved products contain THC.

The law creates a direct collision with this patient population:

• THC impairs driving for roughly 2–6 hours after inhalation, and up to 8–12 hours after oral ingestion.
• THC is detectable in oral fluid for 12–72 hours after use, and in blood at or above New Zealand's criminal threshold of 3 ng/mL for up to 72+ hours in regular or heavy users.
• A patient who took their prescribed cannabis on Friday night and drives to work on Monday morning may still test positive, receive a 12-hour driving ban, and be issued an infringement notice — despite being entirely unimpaired.
• The medical defence under Section 16 of the Act allows prescription holders to contest an infringement notice after it is issued, by demonstrating they held a current valid prescription and followed prescriber or manufacturer instructions. However, this defence cannot be asserted at the roadside — the 12-hour driving prohibition applies regardless of prescription status.
• The 21 prescription medicines covered by the laboratory test include tramadol, all major benzodiazepines (diazepam, lorazepam, temazepam, oxazepam, clonazepam, alprazolam, nitrazepam, triazolam, midazolam), opioids (codeine, dihydrocodeine, morphine, oxycodone, fentanyl, methadone, buprenorphine), zopiclone, and ketamine. Patients taking any of these may be caught in the extended laboratory panel.
• AUT pharmacist Dr Catherine Crofts noted that approximately 50% of New Zealand's ADHD population takes dexamphetamine or lisdexamfetamine, which some tests show cross-reactivity with — yet police have provided no clear guidance on how ADHD medication prescriptions will be handled at the roadside.

Our suggestion: What if we measured impairment, not just presence?

Every drink-driving law in the world is built around a blood-alcohol level that correlates with actual impairment. Drug driving law in New Zealand does something structurally different: it criminalises the presence of a substance, not its effect on driving. A person who last used their prescribed cannabis 48 hours ago, or who took their prescribed tramadol with breakfast, is legally identical to someone who is currently intoxicated behind the wheel. The test cannot distinguish between them.

This is not an argument for tolerating impaired driving — drug-impaired driving is a genuine road safety problem, and the government's statistics on drug involvement in fatal crashes are real. The question is whether a presence-based standard is the right instrument to address it, or whether it catches too many people who pose no actual danger while potentially missing the ones who do. International experience — particularly Australia's 20-year journey from zero-tolerance toward prescription exemptions and threshold-based schemes — suggests the pure presence model has a structural flaw that eventually requires correction. New Zealand may be starting on the same path.

What the evidence says about cannabis and driving impairment

The scientific evidence establishes two things simultaneously: cannabis does impair driving at the time of acute intoxication, and THC detection does not reliably indicate current impairment.

A 2021 meta-analysis of 155 experimental trials confirmed significant impairment of standard deviation of lane position (the gold-standard driving safety measure), reaction time, and tracking accuracy at peak THC. A systematic review found that most driving-relevant cognitive skills recover within approximately 5 hours of inhaling 20mg THC, with near-full recovery by 7 hours. Oral (ingested) THC takes longer — 8–12 hours is the current guideline.

However, THC redistributes rapidly from blood into body tissues. Unlike alcohol, where blood concentration correlates well with behavioural impairment, blood and oral fluid THC levels correlate poorly with driving performance — particularly in regular users who develop tolerance. A November 2025 study published by the Association for Diagnostics and Laboratory Medicine found 43% of research participants exceeded zero-tolerance thresholds at baseline after 48 hours of abstinence; 24% exceeded 2 ng/mL per se limits. Simulator studies found those above and below zero-tolerance cutpoints performed similarly. The AAA Foundation for Traffic Safety found "no scientific basis" for a reliable specific THC blood limit as a per se measure of impairment. The AS/NZS standard used by NZ Police for oral fluid testing itself explicitly states it "is not appropriate to relate the presence of drugs in oral fluid to impairment, but rather to relatively recent exposure."

International experience

• Australia invented oral fluid roadside drug testing in 2004 and applied pure zero-tolerance presence testing for 20 years. Despite 92,875 positive results from 421,217 tests by 2023, drug-related fatal crashes rose from 7.6% to 16.8% of all fatalities over that period. Australia is now actively reforming: Victoria (March 2025) gave courts discretion not to cancel licences for unimpaired prescription holders; New South Wales (June 2026) announced registered medicinal cannabis patients with THC below 50 ng/mL will face no charge.
• United Kingdom sets a blood THC limit of 2 micrograms per litre with a statutory medical defence for prescription users under the Road Traffic Act 1988 — the most legally coherent model for medicinal users, though the threshold was set more strictly than the government's own expert panel recommended.
• Canada, on legalising cannabis in 2018, chose tiered blood THC limits (2 ng/mL and 5 ng/mL) rather than oral fluid presence testing, with Drug Recognition Expert assessments as the primary enforcement tool — explicitly selecting deterrent thresholds rather than a true impairment standard.
• Germany abandoned zero-tolerance cannabis driving law in 2024 and moved to a 3.5 ng/mL blood THC limit, citing scientific evidence that pure zero-tolerance was unjustifiable. New Zealand's current model most closely resembles Australia's 2004–2024 original approach — the model Australia itself is now dismantling.

Expert views

Multiple independent researchers and professional bodies have raised concerns about the law's presence-based design:

Professor Joseph Boden (University of Otago, Christchurch Health and Development Study) wrote that unlike alcohol, "no such relationship exists for THC" between blood concentration and impairment, and that "detection is not prevention." Dr Rose Crossin (University of Otago Public Health) confirmed the test "is only testing for the presence of a drug, not impairment." Dr Fiona Hutton (Victoria University of Wellington, Institute of Criminology) called government drug-in-crash statistics "highly misleading" because drug presence at a crash scene does not establish the driver was impaired at the time. Dr Geoff Noller (University of Otago Primary Health) warned cannabis detection can persist for "8 to 12 hours at least" and up to 30 hours for heavy users — far beyond impairment. Dr Michael White (University of Adelaide), the most-quoted external critic in NZ media, described the approach as "nearly worthless" for detecting actual impairment, noting Australia has had "no evaluation that clearly shows that roadside drug testing actually works." The NZ Medical Association opposed the original bill, stating oral fluid tests "do not detect impairment and correlate poorly with actual blood concentration." The NZ Law Society stated that "using drug presence as a proxy for impairment is scientifically invalid."

Supporters include Superintendent Steve Greally (Director of Road Policing, NZ Police), who argues the testing will deter drug-impaired driving and that "if you intend to get behind the wheel after consuming impairing drugs, you will be caught." The NZ Automobile Association has been a consistent supporter, with 94% of AA members backing the law in surveys.

What the government says

Transport Minister Chris Bishop stated at the December 2025 launch: "Around 30 per cent of all road deaths now involve an impairing drug." The government cites 2019–2022 data showing an average of 105 deaths per year in crashes where a driver had consumed an impairing drug. A broader ESR post-mortem study covering 2013–2018 found that of 1,069 driver fatalities tested, 59% had some substance present. The law was a response to an enforcement gap: previously, police could only require blood testing at a police station if they had reasonable suspicion of impairment — far less effective than the alcohol breath-testing regime which allows random roadside checks anywhere at any time. The Road to Zero strategy (2020–2030) identified drug driving as one of five focus areas; the current government maintained and accelerated the policy after replacing Road to Zero with a three-year Road Safety Objectives framework in October 2024.

Social media and public debate

Public debate is sharply divided. Road safety supporters broadly back the law as a pragmatic deterrent and describe early Wellington pilot feedback as positive. Critics — including medicinal cannabis patients, civil liberties advocates, public health researchers, and Maori community representatives — question whether the law addresses driving danger or polices drug use more broadly. The most frequently raised public questions are: why does the test detect yesterday's cannabis use rather than today's impairment? Why does having a valid prescription offer no protection at the roadside? Will Maori and young people be disproportionately targeted? Early Wellington pilot data (approximately 300 tests, 7 infringement notices — a 2.3% rate) has prompted debate about cost-effectiveness. Petition campaigns opposing the law attracted modest but organised support, and multiple Official Information Act requests have been lodged seeking validation data for the testing device and process.